Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Summary

To evaluate the efficacy of sirolimus by estimating the overall response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) in patients with metastatic dMMR solid cancer after immunotherapy (either due to disease progression or to inability to tolerate treatment).

Timeline

Start

2020-11-16

Primary completion

2023-05-16

Completion

2023-05-16

Outcome

Outcome not reported

Stopped: “Following discussion with the Cancer Center the PI elected to terminate the study.”

Drugs

Indications